

18.	Segment Data

During the fourth quarter of fiscal 2016, the Company announced that it had entered into a definitive agreement to sell its Nuclear Imaging business to IBAM. The Nuclear Imaging business is deemed to be held for sale and the financial results of this business are presented as a discontinued operation. The sale was completed on January 27, 2017.

The two reportable segments are further described below:


•	Specialty Brands includes branded pharmaceutical products and therapies; and


•	Specialty Generics includes specialty generic pharmaceuticals and active pharmaceutical ingredients ("API") consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients.

Selected information by business segment was as follows:



	Three Months Ended
	December 30, 2016			December 25, 2015
Net sales:
Specialty Brands	$	603.1		$	543.2
Specialty Generics	212.9			257.6
Net sales of operating segments	816.0			800.8
Other ⁽¹⁾	13.9			10.4
Net sales	$	829.9		$	811.2
Operating income:
Specialty Brands	$	317.2		$	269.1
Specialty Generics	52.7			115.2
Segment operating income	369.9			384.3
Unallocated amounts:
Corporate and allocated expenses ⁽²⁾	(181.4		)	(44.6		)
Intangible asset amortization	(175.7		)	(173.4		)
Restructuring and related charges, net ⁽³⁾	(5.3		)	(4.2		)
Non-restructuring impairment charges	(214.3		)	—
Operating (loss) income	$	(206.8	)	$	162.1


(1)	Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.


(2)	Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's operating segments.


(3)	Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's segments are as follows:



	Three Months Ended
	December 30, 2016		December 25, 2015
Acthar	$	325.4	$	286.7
Inomax	118.3		110.8
Ofirmev	72.5		66.9
Therakos immunotherapy	47.4		50.4
Hemostasis products	13.4		—
Other	26.1		28.4
Specialty Brands	603.1		543.2

Hydrocodone (API) and hydrocodone-containing tablets	23.2		36.7
Oxycodone (API) and oxycodone-containing tablets	24.3		28.9
Methylphenidate ER	22.0		31.2
Other controlled substances	104.9		109.7
Other products	38.5		51.1
Specialty Generics	212.9		257.6

Other⁽¹⁾	13.9		10.4
Net sales	$	829.9	$	811.2


(1)	Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.